Continuous dopaminergic stimulation: Clinical aspects and experimental bases

Neurologist

Volumn 17, Issue 6 SUPPL., 2011, Pages

  Rodriguez Oroz, Maria Cruz ^a,b,c,f   Marin, Concepción ^d   De Fabregues, Oriol ^e  

^a HOSPITAL DONOSTIA   (Spain)

^b BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^c BASQUE FOUNDATION FOR SCIENCE   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

basal ganglia; continuous dopamine stimulation; dopaminergic treatments; dyskinesia; Parkinson disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ENKEPHALIN; ENTACAPONE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LEVODOPA; LISURIDE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; PREPRODYNORPHIN; PREPROENKEPHALIN; ROPINIROLE; ROTIGOTINE; TETRAHYDROBIOPTERIN; TYROSINE 3 MONOOXYGENASE;

ABDOMINAL PAIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; CLINICAL PRACTICE; CONFUSION; CONTINUOUS DOPAMINERGIC STIMULATION; DENERVATION; DERMATITIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPAMINE METABOLISM; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DNA BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERANCE; DYSKINESIA; GENE THERAPY; GENE TRANSFER; GRANULOMA; HALLUCINATION; HEART MUSCLE FIBROSIS; HUMAN; LOCOMOTION; LONG TERM CARE; MONOTHERAPY; NONHUMAN; PAIN; PARKINSON DISEASE; PERITONITIS; POLYNEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULSATILE DRUG RELEASE; RAT; SKIN MANIFESTATION; STIMULATION; ULCER; VALVULAR HEART DISEASE;

ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; DOPAMINE AGONISTS; DYSKINESIAS; HUMANS; LEVODOPA; NEUROPEPTIDES; PARKINSON DISEASE; RECEPTORS, DOPAMINE; RECEPTORS, GABA-A;

EID: 80455131085     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e31823966e3     Document Type: Article

References (95)

1. Sweet RD, McDowell FH. The "on-off" response to chronic L-DOPA treatment of Parkinsonism. Adv Neurol. 1974;5:331-338.
2. Muenter MD, Tyce GM. L-dopa therapy of Parkinson's disease: Plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc. 1971;46:231-239.
3. Vaamonde J, Luquin MR, Obeso JA. Subcutaneous lisuride infusion in Parkinson's disease: Response to chronic administration in 34 patients. Brain. 1991;114(Pt 1B):601-617.
4. Kempster PA, Frankel JP, Bovingdon M, et al. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1989;52: 718-723.
5. Juncos J, Serrati C, Fabbrini G, et al. Fluctuating levodopa concentrations and Parkinson's disease. Lancet. 1985;2:440.
6. Bedard PJ, Di Paolo T, Falardeau P, et al. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTPparkinsonian monkeys: correlation with [3H]spiperone binding. Brain Res. 1986;379:294-299.
7. Olanow W, Schapira AH, Rascol O. Continuous dopaminereceptor stimulation in early Parkinson's disease. Trends Neurosci. 2000;23(10 Suppl):S117-S126.
8. Pearce RK, Banerji T, Jenner P, et al. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord. 1998;13:234-241.
9. Grondin R, Goulet M, Di Paolo T, et al. Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates. Brain Res. 1996;735:298-306.
10. Blanchet PJ, Calon F, Martel JC, et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTPexposed monkeys. J Pharmacol Exp Ther. 1995;272:854-859.
11. Stockwell KA, Virley DJ, Perren M, et al. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets. Exp Neurol. 2008;211: 172-179.
12. Stockwell KA, Scheller D, Rose S, et al. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. Exp Neurol. 2009;219:533-542.
13. JacksonMJ, Smith LA, Al-Barghouthy G, et al. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTPtreated common marmosets. Exp Neurol. 2007;204:162-170.
14. Henry B, Duty S, Fox SH, et al. Increased striatal preproenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol. 2003;183:458-468.
15. Alexander GM, Schwartzman RJ, Grothusen JR, et al. Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment. Brain Res. 1993;625:276-282.
16. Goulet M, Morissette M, Calon F, et al. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drugnaive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: In situ hybridization histochemical analysis. Neuroscience. 1997;79:497-507.
17. Goulet M, Grondin R, Morissette M, et al. Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian monkeys. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24:607-617.
18. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990;250:1429-1432.
19. Stockwell KA, Scheller DK, Smith LA, et al. Continuous rotigotine administration reduces dyskinesia resulting frompulsatile treatment with rotigotine or L-DOPA in MPTP-treated common marmosets. Exp Neurol. 2010;221:79-85.
20. Duty S, Brotchie JM. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6- hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression. Exp Neurol. 1997;144:423-432.
21. Tayarani-Binazir KA, Jackson MJ, Rose S, et al. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets. Mov Disord. 2010;25:377-384.
22. Marin C, Obeso JA. Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of L-dopa treatment. Int Rev Neurobiol. 2010;95:191-205.
23. Cenci MA, Lee CS, Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphinand glutamic acid decarboxylase mRNA. Eur J Neurosci. 1998; 10:2694-2706.
24. Mandel RJ, Rendahl KG, Spratt SK, et al. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci. 1998;18:4271-4284.
25. Corti O, Sanchez-Capelo A, Colin P, et al. Long-term doxycyclinecontrolled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. Proc Natl Acad Sci U S A. 1999;96:12120-12125.
26. Aubert I, Guigoni C, Hakansson K, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol. 2005;57:17-26.
27. Carlsson T, Winkler C, Burger C, et al. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain. 2005;128(Pt 3):559-569.
28. Carlsson T, Winkler C, Burger C, et al. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain. 2005;128(Pt 3):559-569.
29. Bjorklund T, Carlsson T, Cederfjall EA, et al. Optimized adenoassociated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. Brain. 2010;133(Pt 2):496-511.
30. Mouradian MM, Juncos JL, Fabbrini G, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neurol. 1988;24:372-378.
31. Falardeau P, Bouchard S, Bedard PJ, et al. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. Eur J Pharmacol. 1988; 150:59-66.
32. Palfi S. Towards gene therapy for Parkinson's disease. Lancet Neurol. 2008;7:375-376.
33. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology. 2008;70:1980-1983.
34. Mouradian MM, Heuser IJ, Baronti F, et al. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol. 1990;27:18-23.
35. Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease: Relation to levodopa absorption and transport. N Engl J Med. 1984;310:483-488.
36. Herrero MT, Augood SJ, Asensi H, et al. Effects of L-DOPAtherapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys. Brain Res Mol Brain Res. 1996;42:149-155.
37. Hardie RJ, Malcolm SL, Lees AJ, et al. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J Clin Pharmacol. 1986;22: 429-436.
38. Henry B, Crossman AR, Brotchie JM. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6- hydroxydopamine- lesioned rat. Exp Neurol. 1999;155:204-220.
39. Stocchi F, Ruggieri S, Vacca L, et al. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain. 2002;125(Pt 9):2058-2066.
40. Calon F, Goulet M, Blanchet PJ, et al. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex. Brain Res. 1995;680:43-52.
41. During K. A plant transformation vector with a minimal T-DNA. Transgenic Res. 1994;3:138-140.
42. Bencsics C, Wachtel SR, Milstien S, et al. Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts. J Neurosci. 1996;16:4449-4456.
43. Shen Y, Muramatsu SI, Ikeguchi K, et al. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther. 2000;11: 1509-1519.
44. Muramatsu S, Wang L, Ikeguchi K, et al. Recombinant adenoassociated viral vectors bring gene therapy for Parkinson's disease closer to reality. J Neurol. 2002;249(Suppl 2):II36-II40.
45. Muramatsu S, Wang L, Ikeguchi K, et al. Recombinant adenoassociated viral vectors bring gene therapy for Parkinson's disease closer to reality. J Neurol. 2002;249(Suppl 2):II36-II40.
46. Quinn N, Marsden CD, Parkes JD. Complicated response fluctuations in Parkinson's disease: Response to intravenous infusion of levodopa. Lancet. 1982;2:412-415.
47. Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology. 1984;34:1131-1136.
48. Chase TN, Juncos J, Serrati C, et al. Fluctuation in response to chronic levodopa therapy: Pathogenetic and therapeutic considerations. Adv Neurol. 1987;45:477-480.
49. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs. 1998;55(Suppl 1):23-30.
50. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamineagonist treatment in Parkinson's disease. Lancet Neurol. 2007;6: 826-829.
51. Brime B, Ballesteros MP, Frutos P. Preparation and in vitro characterization of gelatin microspheres containing Levodopa for nasal administration. J Microencapsul. 2000;17:777-784.
52. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs. levodopa in early Parkinson disease. Arch Neurol. 2009;66:563-570.
53. Stocchi F, Giorgi L, Hunter B. Schapira AH.PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Mov Disord. 2011;26:1259-1265.
54. LeWitt PA, Boroojerdi B, MacMahon D, et al. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007;30: 256-265.
55. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68:1108-1115.
56. Ruggieri S, Stocchi F, Carta A, et al. Comparison between L-dopa and lisuride intravenous infusions: A clinical study. Mov Disord. 1988;3:313-319.
57. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa: 056 Study Group. N Engl J Med. 2000;342:1484-1491.
58. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Jama. 2000;284:1931-1938.
59. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: A doubleblind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6:513-520.
60. Watts RL, Lyons KE, Pahwa R, et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord. 2010;25:858-866.
61. Cedarbaum JM, Breck L, Kutt H, et al. Controlled-release levodopa/ carbidopa. II: Sinemet CR4 treatment of response fluctuations in Parkinson's disease.. Neurology. 1987;37:1607-1612.
62. Goetz CG, Tanner CM, Shannon KM, et al. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations. Neurology. 1988;38: 1143-1146.
63. Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease: A multicenter 5-year study. The CR First Study Group. Eur Neurol. 1997;37:23-27.
64. Piccini P, Brooks DJ, Korpela K, et al. The catechol-Omethyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000; 68:589-594.
65. Paija O, Laine K, Kultalahti ER, et al. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. Clin Neuropharmacol. 2005;28:115-119.
66. Sampaio C, Ferreira JJ. Parkinson disease: Adjunctive entacapone therapy increases risk of dyskinesia. Nat Rev Neurol. 2010;6: 590-591.
67. Stocchi F, Rascol O, Kieburtz K, et al, Initiating levodopa/ carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study. Ann Neurol. 2010;68:18-27.
68. Kurlan R, Rubin AJ, Miller C, et al. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: Preliminary observations. Ann Neurol. 1986;20:262-265.
69. Kurlan R, Nutt JG, Woodward WR, et al. Duodenal and gastric delivery of levodopa in parkinsonism. Ann Neurol. 1988;23: 589-595.
70. Frankel JP, Kempster PA, Bovingdon M, et al. The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J Neurol Neurosurg Psychiatry. 1989;52: 1063-1067.
71. Cedarbaum JM, Silvestri M, Kutt H. Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology. 1990;40:995-997.
72. Sage JI, Trooskin S, Sonsalla PK, et al. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol. 1988;24:87-89.
73. Syed N, Murphy J, Zimmerman T Jr, et al. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord. 1998;13:336-338.
74. Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebocontrolled, crossover study of duodenal infusion of levodopa/ carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology. 1993;43:1698-1703.
75. Bredberg E, Nilsson D, Johansson K, et al. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. Eur J Clin Pharmacol. 1993;45:117-122.
76. Nilsson D, Hansson LE, Johansson K, et al. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand. 1998;97:175-183.
77. Sjalander-Brynne L, Paalzow LK. Pharmacodynamic aspects of drug administration: Tolerance development. Adv Drug Deliv Rev. 1998;33:235-240.
78. Stocchi F, Vacca L, Ruggieri S, et al. Intermittent vs. continuous levodopa administration in patients with advanced Parkinson disease: A clinical and pharmacokinetic study. Arch Neurol. 2005; 62:905-910.
79. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord. 2007;22:1145-1149.
80. Antonini A, Mancini F, Canesi M, et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis. 2008;5:244-246.
81. Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: Practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol. 2008;31:151-166.
82. Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: Intestinal infusion versus oral sustained- release tablets. Clin Neuropharmacol. 2003;26:156-163.
83. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs. oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64:216-223.
84. Fabregues OD. Management of complications of long-term duodenal levodopa infusion therapy. Mov Disord. 2008;23: S314-S315.
85. Obeso JA, Grandas F, Vaamonde J, et al. Apomorphine infusion for motor fluctuations in Parkinson's disease. Lancet. 1987;1:1376-1377.
86. Frankel JP, Lees AJ, Kempster PA, et al. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990;53:96-101.
87. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: Response to chronic administration for up to five years. Mov Disord. 1993;8:165-170.
88. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: A long-term follow-up. J Neurol Neurosurg Psychiatry. 1998;65:709-716.
89. Tyne HL, Parsons J, Sinnott A, et al. A 10-year retrospective audit of long-term apomorphine use in Parkinson's disease. J Neurol. 2004;251:1370-1374.
90. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single-dose challenges. Mov Disord. 2005;20:151-157.
91. Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study. Mov Disord. 2008;23:1130-1136.
92. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients. Mov Disord. 2002;17:1235-1241.
93. Antonini A, Tolosa E. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: Selection criteria and patient management. Expert Rev Neurother. 2009;9:859-867.
94. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology. 2008;70:1980-1983.
95. Grace AA. The tonic/phasic model of dopamine system regulation: Its relevance for understanding how stimulant abuse can alter basal ganglia function. Drug Alcohol Depend. 1995;37:111-129.